Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia
Autore:
Lavie, G; Teichner, A; Shohami, E; Ovadia, H; Leker, RR;
Indirizzi:
Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Agnes Ginges Ctr Human Neurogenet,Dept Neurol, IL-91120 Jerusalem, Israel Hebrew Univ Jerusalem Jerusalem Israel IL-91120 -91120 Jerusalem, Israel Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel Hebrew Univ Jerusalem Jerusalem Israel IL-91120 -91120 Jerusalem, Israel Univ Rome, Dept Neurol Sci, Rome, Italy Univ Rome Rome ItalyUniv Rome, Dept Neurol Sci, Rome, Italy
Titolo Testata:
BRAIN RESEARCH
fascicolo: 1-2, volume: 901, anno: 2001,
pagine: 195 - 201
SICI:
0006-8993(20010518)901:1-2<195:LTCEOD>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; INFARCT VOLUME; BRAIN INJURY; HU-211; RAT; NEUROPROTECTANT; APOPTOSIS; NECROSIS; ALPHA;
Keywords:
cerebral ischemia; dexanabinol; HU-211; NMDA; cytokines; free radical;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Leker, RR Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Agnes Ginges Ctr Human Neurogenet,Dept Neurol, Ein Karem,POB 12000, IL-91120 Jerusalem, Israel Hebrew Univ Jerusalem Ein Karem,POB 12000 Jerusalem Israel IL-91120
Citazione:
G. Lavie et al., "Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia", BRAIN RES, 901(1-2), 2001, pp. 195-201

Abstract

In order to test the long-term cerebroprotective effects of dexanabinol, asynthetic non-competitive NMDA antagonist that also has anti-TNF alpha effects, spontaneously hypertensive rats underwent permanent middle cerebral artery occlusion (PMCAO). Rats were given vehicle or dexanabinol (3.5 mg/kg)1. 3 or 6 h after PMCAO. The research consisted of 2 stages. In the short-term set of experiments animals (n=5/group). were tested with a motor disability scale 24 h post PMCAO, then sacrificed and the infarct volume was measured using 2,3.5-Triphenylterrazolium chloride (TTC) staining. In the long-term set of experiments the rats (n=7/group) were examined daily with a motor disability scale up to 30 days after PMCAO and then sacrificed and infarct volumes were determined using TTC staining. Motor scores were significantly improved in the dexanabinol treated rats (P<0.05 for all groups) at all the time points examined. Infarct volumes were significantly reduced 24 hafter PMCAO in the groups treated 1 or 3 h, but not 6 h after PMCAO compared with vehicle (Mean<plus/minus>S.D., 11.5 +/-2.02, 12 +/-3.2 and 14.4 +/-2.4% vs. 20.8 +/-1.3% hemispheric volume respectively). The lesions remained significantly smaller in the dexanabinol groups 30 days after PMCAO (Mean+/-S.D., 24.39 +/-1.9% vs. 8.1 +/-0.6, 11.1 +/-2.3 and 13.8 +/-2.5% hemispheric volume in animals treated with vehicle vs. dexanabinol 1, 3 or 6 h after PMCAO respectively: P<0.05 for all). In conclusion, the extended therapeutic window and the multi-mechanistic durable neuroprotective effects of dexanabinol make it a promising candidate for Future stroke therapy. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 23:46:37